JP2009516747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009516747A5 JP2009516747A5 JP2008542425A JP2008542425A JP2009516747A5 JP 2009516747 A5 JP2009516747 A5 JP 2009516747A5 JP 2008542425 A JP2008542425 A JP 2008542425A JP 2008542425 A JP2008542425 A JP 2008542425A JP 2009516747 A5 JP2009516747 A5 JP 2009516747A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- independently
- carbocyclyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(BC(*1)(*C2(*)*)*C2(*)N[U][U]*)(C2)C12I Chemical compound *C(BC(*1)(*C2(*)*)*C2(*)N[U][U]*)(C2)C12I 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73891905P | 2005-11-22 | 2005-11-22 | |
| US60/738,919 | 2005-11-22 | ||
| PCT/US2006/045151 WO2007062093A2 (en) | 2005-11-22 | 2006-11-21 | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009516747A JP2009516747A (ja) | 2009-04-23 |
| JP2009516747A5 true JP2009516747A5 (https=) | 2010-01-14 |
| JP5256042B2 JP5256042B2 (ja) | 2013-08-07 |
Family
ID=37994504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542425A Expired - Fee Related JP5256042B2 (ja) | 2005-11-22 | 2006-11-21 | 癌の処置のための併用療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8324194B2 (https=) |
| EP (1) | EP1951242A2 (https=) |
| JP (1) | JP5256042B2 (https=) |
| CA (1) | CA2628747C (https=) |
| WO (1) | WO2007062093A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8088737B2 (en) | 2003-04-04 | 2012-01-03 | Incyte Corporation | Compositions, methods and kits relating to Her-2 cleavage |
| EP1622569B1 (en) | 2003-04-24 | 2015-12-02 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metallproteases |
| WO2005037826A1 (en) | 2003-10-17 | 2005-04-28 | Incyte Corporation | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| WO2007016597A2 (en) * | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
| US7910108B2 (en) | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| PT2594590E (pt) | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
| WO2010141543A1 (en) * | 2009-06-02 | 2010-12-09 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
| WO2011083391A2 (en) | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarkers for anti-igf-ir cancer therapy |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| US9822129B2 (en) | 2012-03-02 | 2017-11-21 | Genentech, Inc. | Amido spirocyclic amide and sulfonamide derivatives |
| CN102600073B (zh) * | 2012-03-31 | 2014-01-01 | 莱普德制药有限公司 | 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法 |
| RU2737765C2 (ru) | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин |
| SG10201708048XA (en) | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| US20160060288A1 (en) * | 2013-04-18 | 2016-03-03 | Xi'anlibang Pharmaceutical Technology Co., Ltd. | Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| EP4559477A3 (en) | 2020-05-13 | 2025-08-13 | Adagene AG | Compositions and methods for treating cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008172D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
| NZ524104A (en) * | 2000-09-08 | 2004-12-24 | Pharmacia Italia S | Exemestane as chemopreventing agent |
| MXPA03006607A (es) * | 2001-01-26 | 2003-09-22 | Upjohn Co | Metodo combinado para tratar trastornos dependientes de hormonas. |
| US8088737B2 (en) * | 2003-04-04 | 2012-01-03 | Incyte Corporation | Compositions, methods and kits relating to Her-2 cleavage |
| EP1622569B1 (en) * | 2003-04-24 | 2015-12-02 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metallproteases |
| WO2005037826A1 (en) | 2003-10-17 | 2005-04-28 | Incyte Corporation | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| US20050250789A1 (en) | 2004-04-20 | 2005-11-10 | Burns David M | Hydroxamic acid derivatives as metalloprotease inhibitors |
| US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
-
2006
- 2006-11-21 JP JP2008542425A patent/JP5256042B2/ja not_active Expired - Fee Related
- 2006-11-21 EP EP06838238A patent/EP1951242A2/en not_active Withdrawn
- 2006-11-21 CA CA2628747A patent/CA2628747C/en active Active
- 2006-11-21 US US11/602,659 patent/US8324194B2/en active Active
- 2006-11-21 WO PCT/US2006/045151 patent/WO2007062093A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009516747A5 (https=) | ||
| CA2628747A1 (en) | Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer | |
| US6291505B1 (en) | Estrogen receptor modulators | |
| US7186838B2 (en) | Fluorinated 4-azasteroid derivatives as androgen receptor modulators | |
| CN101243052B (zh) | 螺旋结构12定位的非甾族抗雄激素物质 | |
| JP5595402B2 (ja) | アンドロゲン受容体モジュレーターとしての新規イミダゾリジン化合物 | |
| US10730856B2 (en) | Benzimidazole derivatives as EP4 ligands | |
| US20100331333A1 (en) | Imidazo [1,2-B] Pyridazine Compounds | |
| US10344034B2 (en) | Pyrazolopyrimidone or Pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof | |
| CN101175747A (zh) | 作为选择性雄激素受体调节剂的取代的n-芳基吡咯烷化合物 | |
| WO2004041277A1 (en) | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | |
| JP4607860B2 (ja) | 腫瘍阻害作用を有する抗−アンドロゲン性ピロリジン | |
| JP2002522425A (ja) | エストロゲンレセプターモジュレーターとしての置換イソオキサゾール | |
| CN105873917A (zh) | 含有吡啶基部分的非甾体类抗雄激素和选择性雄激素受体调节剂 | |
| JP2012502975A (ja) | 治療において有用なアミド化合物 | |
| KR20150036319A (ko) | 3-치환된 에스트라-1,3,5(10),16-테트라엔 유도체, 그의 제조방법, 이를 포함하는 약학 제제 및 의약품 제조를 위한 그의 용도 | |
| US20100324073A1 (en) | Pyrazolo [1,5-A] Pyrimidine Compounds | |
| US20230000876A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
| Nakagawa et al. | Progesterone receptor antagonists with a 3-phenylquinazoline-2, 4-dione/2-phenylisoquinoline-1, 3-dione skeleton | |
| ES2264032T3 (es) | Derivados de n-fenilamino-1h-imidazol como inhibidores de la aromatasa. | |
| WO2020063407A1 (zh) | N-芳香酰胺类化合物及其制备方法和用途 | |
| Choi | Structure-property relationships reported for the new drugs approved in 2023 | |
| US6737433B1 (en) | 1-N-phenylamino-1H-imidazole derivatives as aromatase inhibitors and pharmaceutical compositions containing them | |
| HK1223609B (zh) | 含有吡啶基部分的非甾体类抗雄激素和选择性雄激素受体调节剂 | |
| CN122003428A (zh) | 不可逆17β-HSD1抑制剂 |